Biotech & AI drug discoveryNature Medicine

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Nature Medicine published results from the randomized phase 2 PHERGain trial, reporting 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer along with exploratory circulating tumor DNA analyses.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-29T00:00:00+00:00

Published here2026-11-01T20:18:35+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04723-w

Original headline

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.